Converge Bio

Begin with a narrowly defined scientific or clinical-development question that matches Converge Bio's purpose: generative AI drug discovery platform for biological target analysis, antibody work, protein expression, and therapeutic research. Document the target, endpoint, assay, cohort, protocol, or decision criterion before running the AI workflow so the team can judge whether the output is actually useful.

Use high-quality source data and keep provenance attached to every important result. For molecular or protein design, retain the model version, sequence or structure inputs, scoring criteria, and experimental follow-up. For clinical-data or trial workflows, preserve cohort definitions, inclusion and exclusion logic, source-record links, and investigator review.

Evaluate prospective performance rather than only attractive retrospective examples. Track false positives, false negatives, failed experiments, uncertainty, and subgroup behavior. Do not promote a computational prediction into a biological fact, patient-level conclusion, or trial decision without the appropriate experimental or clinical validation.

Before production or regulated use, review privacy, consent, data licensing, security, auditability, model validation, reproducibility, regional requirements, and human oversight. Pricing is currently classified as contact, but confirm current commercial terms with the provider.